GLMD Galmed Pharmaceuticals Ltd.
USHealthcareAs of 2026-07-09 16:00
Why GLMD matters now
Galmed Pharmaceuticals Ltd. (GLMD) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.57 with +0.00% on the session and $3.1M in market capitalization; recent performance reads 1-month +0.92% and YTD -22.72%.
The latest financial table shown here is Q4 2025, with revenue of $0.00, net income of $-4.8M, and EPS of $-0.73. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -198.7%.
The latest indexable market news headline is "Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd." from PRNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $—. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.24
P/S
0.00
EV/EBITDA
0.08
DCF Value
$0.51
FCF Yield
-198.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-57.0%
ROA
-55.3%
ROIC
-53.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-4.8M | $-0.73 |
| FY 2025 | $0.00 | $-10.3M | $-2.39 |
| Q3 2025 | $0.00 | $-1.9M | $-0.35 |
| Q2 2025 | $0.00 | $-2.5M | $-0.63 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
IL
Exchange
—
Beta
0.71
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for liver diseases. Its primary pipeline candidate is Aramchol, an orally administered drug currently undergoing Phase III clinical trials. This pivotal study is for the treatment of non-alcoholic steato-hepatitis (NASH) in individuals who are overweight or obese and also present with pre-diabetes or type 2 diabetes. Aramchol is also being investigated in the Phase IIa ARRIVE Study, which targets HIV-associated non-alcoholic fatty liver disease and lipodystrophy. Beyond Aramchol, the company is developing Amilo-5MER, a synthetic peptide composed of five specific amino acids: methionine, threonine, alanine, aspartic acid, and valine. Galmed has established several strategic collaborations, including: A research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy for NASH, merging ASC41 (a THR-beta agonist) with Aramchol (an SCD1 inhibitor). A research and development partnership with MyBiotics Pharma Ltd. to identify specific microbiome profiles linked to how patients respond to Aramchol. A licensing agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in South Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is based in Tel Aviv, Israel.